Related Experiment Videos

Patau syndrome with a long survival. A case report

A C Duarte1, A I C Menezes, E S Devens

  • 1Serviço de Aconselhamento Genético do Departamento de Zoologia e Genética, Instituto de Biologia, Universidade Federal de Pelotas, RS, Brasil.

Insights

This case study details a female infant with Trisomy 13, who survived to 28 months. Despite severe developmental delays, physiotherapy and recreation led to noticeable improvements in her condition.

Area of Science:

  • Genetics
  • Pediatrics
  • Clinical Case Study

Background:

  • Trisomy 13 (Patau syndrome) is a severe chromosomal disorder with a high mortality rate, typically affecting infants within the first year of life.
  • The condition is characterized by a wide range of congenital anomalies affecting multiple organ systems.

Observation:

  • A 28-month-old female presented with Trisomy 13, exhibiting typical features such as polydactyly, clubfoot, ocular hypertelorism, and cardiomegaly.
  • The patient experienced significant neuropsychomotor developmental retardation from birth.
  • Despite the severity of Trisomy 13, the child demonstrated notable improvements following physiotherapy and recreational therapy.

Findings:

  • This case highlights an unusual survival of a child with Trisomy 13 beyond the typical infant mortality period.
  • The report documents the physical and developmental trajectory of the patient, including anthropometric measurements up to 28 months.
  • The study underscores the potential benefits of early intervention and supportive therapies in managing developmental challenges associated with Trisomy 13.

Implications:

  • This case contributes to the understanding of the phenotypic variability and long-term prognosis in Trisomy 13.
  • It emphasizes the importance of multidisciplinary care, including physical and recreational therapies, in improving the quality of life for children with chromosomal abnormalities.
  • Further research into the factors influencing survival and developmental outcomes in Trisomy 13 is warranted.